Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-324
Micah J. Maxwell, A. Arnold, Heather Sweeney, Ljun Chen, T. Lih, M. Schnaubelt, C. Eberhart, Jeffrey A. Rubens, Hui Zhang, D. Clark, E. Raabe
{"title":"Abstract 324: Unbiased proteomic and phosphoproteomic analysis identifies response signatures and novel susceptibilities after combined MEK and mTOR inhibition in BRAFV600Emutant glioma","authors":"Micah J. Maxwell, A. Arnold, Heather Sweeney, Ljun Chen, T. Lih, M. Schnaubelt, C. Eberhart, Jeffrey A. Rubens, Hui Zhang, D. Clark, E. Raabe","doi":"10.1158/1538-7445.AM2021-324","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-324","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79849264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-267
S. Nagaraju, Alexis van Venrooy, P. Hensley, K. Bree, C. Ayala-Orozco, N. Brooks, D. Izhaky, J. Tour, A. Kamat
{"title":"Abstract 267: Light-activated molecular nanomachines kill bladder cancer cells","authors":"S. Nagaraju, Alexis van Venrooy, P. Hensley, K. Bree, C. Ayala-Orozco, N. Brooks, D. Izhaky, J. Tour, A. Kamat","doi":"10.1158/1538-7445.AM2021-267","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-267","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79946325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-319
A. DelaCourt, A. Mehta, Alyson P. Black, R. Drake, P. Angel, Y. Hoshida
{"title":"Abstract 319: MALDI-IMS of N-glycan profiles of molecular subclasses of human hepatocellular carcinoma","authors":"A. DelaCourt, A. Mehta, Alyson P. Black, R. Drake, P. Angel, Y. Hoshida","doi":"10.1158/1538-7445.AM2021-319","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-319","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91299719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-17
Liwei Cao, Chen Huang, D. Zhou, O. Bathe, Daniel W. Chan, R. Hruban, Lisha Ding, Bing Zhang, Hui Zhang
{"title":"Abstract 17: Proteogenomic characterization of pancreatic ductal adenocarcinoma","authors":"Liwei Cao, Chen Huang, D. Zhou, O. Bathe, Daniel W. Chan, R. Hruban, Lisha Ding, Bing Zhang, Hui Zhang","doi":"10.1158/1538-7445.AM2021-17","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-17","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77891862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-305
G. Adams, Kai Ma, A. Venkatesan, F. Chen, Feixuan Wu, Melik Z. Turker, Thomas C. Gardinier, Pei-Ming Chen, Vaibhav Patel, E. Bayever, Paul Rudick, Geno Germano
CDCs are novel ultra-small (6-7 nm) nanoparticle drug conjugates that have been demonstrated to be capable of faster tumor targeting and deeper tumor penetration than antibody drug conjugates in animal models. CDCs are capable of targeting tumors in the brain and pancreas that are difficult to access, while exhibiting limited exposure to normal tissues due their efficient renal elimination. CDCs are composed of a silica core, in which Cy5, a far red dye is covalently encapsulated. The silica core is covalently coated with a layer of polyethylene glycol which is then functionalized with targeting moieties and payloads. ELU001 is a CDC functionalized with ~20 molecules of the topoisomerase-1 inhibitor exatecan linked via a proteolytic cleavable linker as a payload and ~15 folic acids to provide targeting to FRα overexpressing cancers. ELU001 is rapidly internalized into FRα expressing cells and is trafficked to the lysosome where the payload is released from the CDC. ELU001 exhibits potency in the low single digit nanomolar to sub-nanomolar range against cancer cells that express 3+ (KB, IGROV-1) and 2+ (SK-OV-3, HCC827 and OVCAR-3) levels of FRα after a 6-hr exposure in a 7-day viability study. In contrast, an anti-FRα ADC based ADC mirvetuximab soravtansine exhibits lower potency (>100 nM IC50) against SK-OV-3 and HCC827 cells and 40 nM IC50 against OVCAR-3 cells. ELU001 exhibits potent efficacy against established s.c. KB human cervical tumor xenografts in immunodeficient mice with significantly better efficacy and safety than free exatecan payload. It is also effective in treating established SK-OV-3 tumors with lower (2+) FRα expression, a setting where the ADC is again less effective. IND-enabling nonclinical studies are currently underway to prepare for initiation of a first-in-human phase 1 clinical trial in subjects with FRα overexpressing cancers in the second half of 2021. Citation Format: Gregory Paul Adams, Kai Ma, Aranapakam Venkatesan, Feng Chen, Fei Wu, Melik Turker, Thomas Gardinier, Peiming Chen, Vaibhav Patel, Eliel Bayever, Paul Rudick, Geno Germano. ELU001, a targeted C9Dot drug conjugate (CDC) for the treatment of folate receptor alpha (FRα) overexpressing cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 305.
cdc是一种新型的超小(6-7纳米)纳米药物偶联物，在动物模型中已被证明能够比抗体药物偶联物更快地靶向肿瘤和更深地穿透肿瘤。cdc能够靶向难以进入的脑和胰腺肿瘤，同时由于其有效的肾脏消除作用，对正常组织的暴露有限。cdc由硅芯组成，其中Cy5(一种远红色染料)被共价包裹。二氧化硅核心共价涂覆一层聚乙二醇，然后用靶向部分和有效载荷功能化。ELU001是一种CDC功能化药物，含有约20个拓扑异构酶-1抑制剂exatecan分子，通过蛋白水解可切割连接物作为有效载荷，以及约15种叶酸，用于靶向FRα过表达的癌症。ELU001被迅速内化到表达FRα的细胞中，并被运输到溶酶体，在那里有效载荷从CDC释放。在一项为期7天的生存研究中，ELU001对表达3+ (KB, IGROV-1)和2+ (SK-OV-3, HCC827和OVCAR-3)水平的FRα的癌细胞在暴露6小时后显示出低个位数纳摩尔至亚纳摩尔范围内的效力。相比之下，基于抗fr α ADC的ADC mirvetuximab soravtansine对SK-OV-3和HCC827细胞的IC50值>100 nM，对OVCAR-3细胞的IC50值为40 nM。ELU001在免疫缺陷小鼠中对已建立的s.c. KB人子宫颈肿瘤异种移植物具有强大的疗效，其疗效和安全性明显优于游离艾替替康。它也有效地治疗具有较低(2+)FRα表达的已建立的SK-OV-3肿瘤，这也是ADC效果较差的情况。支持ind的非临床研究目前正在进行中，以准备在2021年下半年启动针对FRα过表达癌症患者的首次人体i期临床试验。引用格式:Gregory Paul Adams, Kai Ma, Aranapakam Venkatesan, Feng Chen, Fei Wu, Melik Turker, Thomas Gardinier, Peiming Chen, Vaibhav Patel, Eliel Bayever, Paul Rudick, Geno Germano。ELU001是一种靶向C9Dot药物偶联物(CDC)，用于治疗叶酸受体α (FRα)过表达的癌症[摘要]。见:美国癌症研究协会2021年年会论文集;2021年4月10日至15日和5月17日至21日。费城(PA): AACR;癌症杂志，2021;81(13 -增刊):305。
{"title":"Abstract 305: ELU001, a targeted C'Dot drug conjugate (CDC) for the treatment of folate receptor alpha (FRα) overexpressing cancers","authors":"G. Adams, Kai Ma, A. Venkatesan, F. Chen, Feixuan Wu, Melik Z. Turker, Thomas C. Gardinier, Pei-Ming Chen, Vaibhav Patel, E. Bayever, Paul Rudick, Geno Germano","doi":"10.1158/1538-7445.AM2021-305","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-305","url":null,"abstract":"CDCs are novel ultra-small (6-7 nm) nanoparticle drug conjugates that have been demonstrated to be capable of faster tumor targeting and deeper tumor penetration than antibody drug conjugates in animal models. CDCs are capable of targeting tumors in the brain and pancreas that are difficult to access, while exhibiting limited exposure to normal tissues due their efficient renal elimination. CDCs are composed of a silica core, in which Cy5, a far red dye is covalently encapsulated. The silica core is covalently coated with a layer of polyethylene glycol which is then functionalized with targeting moieties and payloads. ELU001 is a CDC functionalized with ~20 molecules of the topoisomerase-1 inhibitor exatecan linked via a proteolytic cleavable linker as a payload and ~15 folic acids to provide targeting to FRα overexpressing cancers. ELU001 is rapidly internalized into FRα expressing cells and is trafficked to the lysosome where the payload is released from the CDC. ELU001 exhibits potency in the low single digit nanomolar to sub-nanomolar range against cancer cells that express 3+ (KB, IGROV-1) and 2+ (SK-OV-3, HCC827 and OVCAR-3) levels of FRα after a 6-hr exposure in a 7-day viability study. In contrast, an anti-FRα ADC based ADC mirvetuximab soravtansine exhibits lower potency (>100 nM IC50) against SK-OV-3 and HCC827 cells and 40 nM IC50 against OVCAR-3 cells. ELU001 exhibits potent efficacy against established s.c. KB human cervical tumor xenografts in immunodeficient mice with significantly better efficacy and safety than free exatecan payload. It is also effective in treating established SK-OV-3 tumors with lower (2+) FRα expression, a setting where the ADC is again less effective. IND-enabling nonclinical studies are currently underway to prepare for initiation of a first-in-human phase 1 clinical trial in subjects with FRα overexpressing cancers in the second half of 2021. Citation Format: Gregory Paul Adams, Kai Ma, Aranapakam Venkatesan, Feng Chen, Fei Wu, Melik Turker, Thomas Gardinier, Peiming Chen, Vaibhav Patel, Eliel Bayever, Paul Rudick, Geno Germano. ELU001, a targeted C9Dot drug conjugate (CDC) for the treatment of folate receptor alpha (FRα) overexpressing cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 305.","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"571 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77786844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-313
A. S. Bawadood, F. Al-Abbasi, A. El-Halawany, A. M. Al-Abd
Breast cancer is one of the most common female cancers and contributes 25.4% of the total diagnosed malignancies in women in 2018. Shogaol, paradol, and gingerol are obtained from many plants belonging to the family Zingiberaceae such as dried ginger and grain of paradise and shows different pharmacological activities. The current study evaluated the anticancer potential of these compounds in combination with chemotherapeutic platinum drugs against breast cancer cells. Cytotoxicity assay, apoptosis assay, immunofluorescent staining cell surface marker analysis, and wound healing assay were used for evaluating the cytotoxic potential of these compounds alone and in combination with platinum chemotherapeutics agents against naive and resistant breast cancer cell lines (MDA-MB-231 and MCF-7adr, respectively). Platinum drugs showed synergism in combination with shogaol and gingerol against the resistant breast cancer cells (MCF-7adr) with a Combination Index (CI) values of 0.39 and 0.54, respectively. A significant increase was observed in the percentages of early and late apoptotic cells for MDA-MB-231 cells treated with 6-shogaol for 24h. Significant decrease in CD44+/CD24- subpopulation was recorded in both cell lines using flowcytometric analysis. In the Wound healing assay, cells treated with the test compounds migrated significantly slower than control and needed a longer time to heal the scratch. In conclusion, gingerol, shogaol, and paradol compounds showed synergistic cytotoxicity with platinum-based drug and augmented their migration inhibitory activity, apoptotic effects, and tumor-associated stem cell suppressive the potential within naive and resistant breast cancer cells. Citation Format: Aziza S. Bawadood, Fahad A. Al-Abbasi, Ali M. El-Halawany, Ahmed M. Al-Abd. Synergistic interaction between gingerol, shogaol and paradol with platinum-based chemotherapeutic drugs against naive and resistant breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 313.
乳腺癌是最常见的女性癌症之一，占2018年女性确诊恶性肿瘤总数的25.4%。Shogaol、paradol和gingerol分别从姜科植物干姜和天堂粮中提取，具有不同的药理活性。目前的研究评估了这些化合物与化疗铂类药物联合治疗乳腺癌细胞的抗癌潜力。采用细胞毒性试验、细胞凋亡试验、免疫荧光染色细胞表面标记分析和伤口愈合试验来评估这些化合物单独使用和与铂类化疗药物联合使用对初发和耐药乳腺癌细胞系(分别为MDA-MB-231和MCF-7adr)的细胞毒性潜力。铂类药物联合shogaol、gingerol对耐药乳腺癌细胞MCF-7adr有协同作用，联合指数(CI)分别为0.39、0.54。6-shogaol作用24h后，MDA-MB-231细胞的早期和晚期凋亡细胞百分比显著增加。流式细胞术分析显示，两种细胞系中CD44+/CD24-亚群显著降低。在伤口愈合试验中，用测试化合物处理的细胞迁移速度明显慢于对照组，并且需要更长的时间来愈合划痕。综上所述，姜辣素、姜酚和酚类化合物与铂基药物表现出协同细胞毒性，增强了它们在初发和耐药乳腺癌细胞中的迁移抑制活性、凋亡作用和肿瘤相关干细胞抑制潜力。引文格式:Aziza S. Bawadood, Fahad A. Al-Abbasi, Ali M. El-Halawany, Ahmed M. Al-Abd。姜辣素、shogaol和paradol与铂类化疗药物对初发和耐药乳腺癌细胞的协同作用[摘要]。见:美国癌症研究协会2021年年会论文集;2021年4月10日至15日和5月17日至21日。费城(PA): AACR;癌症杂志，2021;81(13 -增刊):摘要第313期。
{"title":"Abstract 313: Synergistic interaction between gingerol, shogaol and paradol with platinum-based chemotherapeutic drugs against naïve and resistant breast cancer cells","authors":"A. S. Bawadood, F. Al-Abbasi, A. El-Halawany, A. M. Al-Abd","doi":"10.1158/1538-7445.AM2021-313","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-313","url":null,"abstract":"Breast cancer is one of the most common female cancers and contributes 25.4% of the total diagnosed malignancies in women in 2018. Shogaol, paradol, and gingerol are obtained from many plants belonging to the family Zingiberaceae such as dried ginger and grain of paradise and shows different pharmacological activities. The current study evaluated the anticancer potential of these compounds in combination with chemotherapeutic platinum drugs against breast cancer cells. Cytotoxicity assay, apoptosis assay, immunofluorescent staining cell surface marker analysis, and wound healing assay were used for evaluating the cytotoxic potential of these compounds alone and in combination with platinum chemotherapeutics agents against naive and resistant breast cancer cell lines (MDA-MB-231 and MCF-7adr, respectively). Platinum drugs showed synergism in combination with shogaol and gingerol against the resistant breast cancer cells (MCF-7adr) with a Combination Index (CI) values of 0.39 and 0.54, respectively. A significant increase was observed in the percentages of early and late apoptotic cells for MDA-MB-231 cells treated with 6-shogaol for 24h. Significant decrease in CD44+/CD24- subpopulation was recorded in both cell lines using flowcytometric analysis. In the Wound healing assay, cells treated with the test compounds migrated significantly slower than control and needed a longer time to heal the scratch. In conclusion, gingerol, shogaol, and paradol compounds showed synergistic cytotoxicity with platinum-based drug and augmented their migration inhibitory activity, apoptotic effects, and tumor-associated stem cell suppressive the potential within naive and resistant breast cancer cells. Citation Format: Aziza S. Bawadood, Fahad A. Al-Abbasi, Ali M. El-Halawany, Ahmed M. Al-Abd. Synergistic interaction between gingerol, shogaol and paradol with platinum-based chemotherapeutic drugs against naive and resistant breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 313.","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90300169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-21
N. Beaton, Yuehan Feng, R. Bruderer, Adam Hendricks, Ghaith M. Hamza, Eric Miele, Rick Davies, K. Beeler, Ilaria Piazza, P. Picotti, P. Castaldi, L. Reiter
{"title":"Abstract 21: LiP-MS, a machine learning-based chemoproteomic approach to identify drug targets in complex proteomes","authors":"N. Beaton, Yuehan Feng, R. Bruderer, Adam Hendricks, Ghaith M. Hamza, Eric Miele, Rick Davies, K. Beeler, Ilaria Piazza, P. Picotti, P. Castaldi, L. Reiter","doi":"10.1158/1538-7445.AM2021-21","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-21","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73927834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-320
A. Mehta, Mengjun Wang, Connor A. West, Alyson P. Black, P. Angel, Richard Drakje
{"title":"Abstract 320: Glycan analysis from tissue to serum, identification and validation of a biomarker for the early detection of hepatocellular carcinoma","authors":"A. Mehta, Mengjun Wang, Connor A. West, Alyson P. Black, P. Angel, Richard Drakje","doi":"10.1158/1538-7445.AM2021-320","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-320","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89445597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-285
Chahrazed Bouzriba, Atziri Corin Chavez Alvarez, Mathieu Gagné-Boulet, J. Lacroix, M. Côté, René C.-Gaudrault, S. Fortin
{"title":"Abstract 285: Development of phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as new antimitotic cytochrome P450 1A1-activated prodrugs selective toward breast cancers: Evaluation of branched alkyl chains","authors":"Chahrazed Bouzriba, Atziri Corin Chavez Alvarez, Mathieu Gagné-Boulet, J. Lacroix, M. Côté, René C.-Gaudrault, S. Fortin","doi":"10.1158/1538-7445.AM2021-285","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-285","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"1994 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82428663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：